Prof. Abhay H Pande is affiliated to the Department of Biotechnology, National Institute of Pharmaceutical Education and Research, SAS Nagar. Prof. Pande completed his M.Sc. degree in Biochemistry (from Nagpur University) and obtained his Ph.D. degree in Life Sciences (from Devi Ahilya Vishwavidyalaya, Indore). He then worked as a post-doctoral researcher at prestigious national and international laboratories. Subsequently, he joined as a Lecturer at the Department of Biological Sciences, BITS-Pilani. Later, Prof. Pande moved to NIPER, SAS Nagar where he established his research group which is involved in the development of protein biopharmaceuticals (. Prof. Pande has extensive experience (> 25 years) in the field of protein research (biochemistry, bioinformatics and biotechnology). He is applying his experience to comprehend the structure and function of clinically important proteins, as well as to engineer and develop therapeutic proteins.
Antigen Specificity: A Fluctuating Aspect in the Development of Clinical Antibodies? Sandeep, Suraj H. Shinde, Abhay H. Pande APMIS, 2025 Development of antibodies for clinical use is a complex process involving numerous aspects, with antigen specificity being the most important. Initially, polyclonal antibodies, that can recognize multiple specific and nonspecific antigens (polyreactive), were developed and were very effective in the treatments. Later on, the polyspecificity/polyreactivity of these polyclonal antibodies (binding to multiple antigens) raised concerns about therapeutic efficacy because of their nonspecific interactions and challenges, such as development of immune complexes, batch‐to‐batch variability. This highlighted the need for more targeted approaches. It was resolved by the marked invention of hybridoma technology in 1975 which resulted in the revolution in the antibody development field by offering monoclonal monospecific antibodies (bind single antigen). However, their limited application in complex pathologies sparked a paradigm shift, leading to the resurgence of polyspecific antibodies in the form of monoclonal polyspecific antibodies (Polybodies), which bind multiple antigens, but specifically. Till today, 14 Polybodies are approved for clinical use. This fluctuation in antigen specificity is directing the evolution of engineered antibodies that are going to drive the biopharmaceutical sector in the coming years. Through this write‐up, we assert the fluctuating nature of antigen specificity during the antibody development and how it will be crucial for advancing biologics.
Engineered polyspecific antibodies: A new frontier in the field of immunotherapeutics Sandeep, Suraj H. Shinde, Sakeel Ahmed, Shyam Sunder Sharma, Abhay H. Pande Immunology, 2024 The 21st‐century beginning remarked with the huge success of monospecific MAbs, however, in the last couple of years, polyspecific MAbs (PsAbs) have been an interesting topic and show promise of being biobetter than monospecific MAbs. Polyspecificity, in which a single antibody serves multiple specific target binding, has been hypothesized to contribute to the development of a highly effective antibody repertoire for immune defence. This polyspecific MAb trend represents an explosion that is gripping the whole pharmaceutical industry. This review is concerned with the current development and quality enforcement of PsAbs. All provided literature on monospecific MAbs and polyspecific MAbs (PsAbs) were searched using various electronic databases such as PubMed, Google Scholar, Web of Science, Elsevier, Springer, ACS, Google Patent and books via the keywords Antibody engineering, Polyspecific antibody, Conventional antibody, non‐conventional antibody, and Single domain antibody. In the literature, there are more than 100 different formats to construct PsAb by quadroma technology, chemical conjugation and genetic engineering. Till March 2023, nine PsAb have been approved around the world, and around 330 are in advanced developmental stages, showing the dominancy of PsAb in the growing health sector. Recent advancements in protein engineering techniques and the fusion of non‐conventional antibodies have made it possible to create complex PsAbs that demonstrate higher stability and enhanced potency. This marks the most significant achievement for cancer immunotherapy, in which PsAbs have immense promise. It is worth mentioning that seven out of the nine PsAbs have been approved as anti‐cancer therapy. As PsAbs continue to acquire prominence, they could pave the way for the development of novel immunotherapies for multiple diseases.
Engineering and Partial Characterization of an Anti-IL-23/Anti-TNF-α Bispecific Domain Antibody Fused to Human Serum Albumin Domain for Inflammatory Disease Therapy SH Shinde, S Ahmed, SS Sharma, AH Pande Applied Biochemistry and Biotechnology, 1-19 , 2026 2026
The rise of bispecific T-cell engager (BsTCE) antibodies: A potentially game-changing approach for breast cancer therapy? PU Gudavalekar, PY Khandave, S Shalini, S Selvaraju, AH Pande Drug Discovery Today, 104670 , 2026 2026
Development and partial characterization of fused human endostatin J Anakha, YR Prasad, S Chakka, SS Chaurasia, AH Pande Protein Expression and Purification, 106922 , 2026 2026
Journey of therapeutic antibodies: from discovery to future AH Pande, J Anakha Exploration of Drug Science 4, 1008155 , 2026 2026
Efficacy and safety of transcutaneous electrical nerve stimulation versus oxybutynin in the treatment of overactive bladder in children: a systematic review and meta-analysis D Neharkar, AH Pande, NJ Peters, J Singh, B Medhi, A Prakash, ... International Urology and Nephrology 58 (2), 381-389 , 2026 2026 Citations: 1
Photosensitizer-Antibody Conjugates (PhotoBodies): Emerging Frontiers in the Field of Theranostics (Dec, 10.1007/s11095-025-03975-4, 2025) SS Kulkarni, PY Khandave, AK Tiwatane, K Rawat, J Bhaumik, AH Pande PHARMACEUTICAL RESEARCH , 2026 2026
Correction: Photosensitizer-Antibody Conjugates (PhotoBodies): Emerging Frontiers in the Field of Theranostics SS Kulkarni, PY Khandave, AK Tiwatane, K Rawat, J Bhaumik, AH Pande Pharmaceutical Research, 1-2 , 2026 2026
Lignin-based biopharmaceuticals from nature to medicine: current trends, future prospects and emerging challenges K Rawat, R Kaur, AK Pujari, K Gogde, D Mohne, S Kirar, YN Reddy, ... RSC Applied Interfaces , 2026 2026
Challenges and advances in the development of antidotes against A-series nerve agents RK Tripathy, K Goyal, PY Khandave, J Bzdrenga, X Brazzolotto, F Nachon, ... Archives of Toxicology 100 (1), 15-25 , 2026 2026
Radioligand–Antibody Conjugates: Integrating Antibody Engineering, Chelator Chemistry, and Radioligands for Precision Theranosis PY Khandave, PU Gudavalekar, T Das, AH Pande Molecular Diagnosis & Therapy, 1-22 , 2025 2025 Citations: 1
Photosensitizer-Antibody Conjugates (PhotoBodies): Emerging Frontiers in the Field of Theranostics SS Kulkarni, PY Khandave, AK Tiwatane, K Rawat, J Bhaumik, AH Pande Pharmaceutical Research, 1-14 , 2025 2025 Citations: 3
Polybodies for the treatment of respiratory syncytial virus infection YR Prasad, PY Khandave, AH Pande Drug Discovery Today, 104572 , 2025 2025 Citations: 1
Chemotherapeutic drug—antibody conjugates (ChemoBodies): recent advances and future directions AK Tiwatane, PY Khandave, SS Kulkarni, K Oisaki, AH Pande Current Oncology Reports, 1-25 , 2025 2025 Citations: 3
Cardioprotective Potential of ApoE-Derived Peptide (ApoEFrag) in Myocardial Infarction in Rats: A Mechanistic Study S Ahmed, M Rihan, AH Pande, SS Sharma ACS Pharmacology & Translational Science 8 (8), 2431-2447 , 2025 2025 Citations: 2
Biochemical characterization of a trypsin-chymotrypsin inhibitor from Vigna AH Pande, N Hajela, K Hajela Recent Advances of Research in Antinutritional Factors in Legume Seeds and … , 2025 2025
Amino acid deprivation vs. mainstream cancer therapeutics: exploring the potential and limitations AH Pande, Y Rajendra Prasad, J Anakha Future Oncology 21 (15), 1823-1825 , 2025 2025
Therapeutic Use of ApoE-Mimetic Peptides S Ahmed, AH Pande, SS Sharma Apolipoprotein E: From Biochemistry and Biology to Translational Medicine, 1-20 , 2025 2025
Neuroprotective potential of ApoE-mimetic peptide (ApoEFrag) in stroke models: Neurobehavioural and mechanistic study S Ahmed, RK Tripathy, AH Pande, SS Sharma International Journal of Biological Macromolecules 304, 140790 , 2025 2025 Citations: 8
Bispecific domain antibody attenuates airway hyperresponsiveness and pulmonary inflammation in ovalbumin-lipopolysaccharide induced asthma model by inhibiting IL-23 and TNF-α CK Gala, AH Pande, SS Sharma Pulmonary Pharmacology & Therapeutics 88, 102347 , 2025 2025 Citations: 3
Endostatin in disease modulation: From cancer to beyond J Anakha, YR Prasad, AH Pande Vascular Pharmacology 158, 107459 , 2025 2025 Citations: 13
MOST CITED SCHOLAR PUBLICATIONS
Membrane fluidity is a key modulator of membrane binding, insertion, and activity of 5-lipoxygenase AH Pande, S Qin, SA Tatulian Biophysical journal 88 (6), 4084-4094 , 2005 2005 Citations: 147
Conformational instability of the cholera toxin A1 polypeptide AH Pande, P Scaglione, M Taylor, KN Nemec, S Tuthill, D Moe, ... Journal of molecular biology 374 (4), 1114-1128 , 2007 2007 Citations: 95
The pertussis toxin S1 subunit is a thermally unstable protein susceptible to degradation by the 20S proteasome AH Pande, D Moe, M Jamnadas, SA Tatulian, K Teter Biochemistry 45 (46), 13734-13740 , 2006 2006 Citations: 71
Studies on a Doubleheaded Protease Inhibitor from Phaseolus mungo N Hajela, AH Pande, S Sharma, DN Rao, K Hajela Journal of Plant Biochemistry and Biotechnology 8 (1), 57-60 , 1999 1999 Citations: 69
Modulation of human 5-lipoxygenase activity by membrane lipids AH Pande, D Moe, KN Nemec, S Qin, S Tan, SA Tatulian Biochemistry 43 (46), 14653-14666 , 2004 2004 Citations: 66
Stabilization of the tertiary structure of the cholera toxin A1 subunit inhibits toxin dislocation and cellular intoxication S Massey, T Banerjee, AH Pande, M Taylor, SA Tatulian, K Teter Journal of molecular biology 393 (5), 1083-1096 , 2009 2009 Citations: 61
The N-terminal α-helix of pancreatic phospholipase A2 determines productive-mode orientation of the enzyme at the membrane surface S Qin, AH Pande, KN Nemec, SA Tatulian Journal of molecular biology 344 (1), 71-89 , 2004 2004 Citations: 58
Evidence for the regulatory role of the N-terminal helix of secretory phospholipase A2 from studies on native and chimeric proteins S Qin, AH Pande, KN Nemec, X He, SA Tatulian Journal of Biological Chemistry 280 (44), 36773-36783 , 2005 2005 Citations: 54
Positioning membrane proteins by novel protein engineering and biophysical approaches SA Tatulian, S Qin, AH Pande, X He Journal of Molecular Biology 351 (5), 939-947 , 2005 2005 Citations: 53
Isoform-specific membrane insertion of secretory phospholipase A2 and functional implications AH Pande, S Qin, KN Nemec, X He, SA Tatulian Biochemistry 45 (41), 12436-12447 , 2006 2006 Citations: 43
Oxidatively modified fatty acyl chain determines physicochemical properties of aggregates of oxidized phospholipids AH Pande, S Kar, RK Tripathy Biochimica et Biophysica Acta (BBA)-Biomembranes 1798 (3), 442-452 , 2010 2010 Citations: 36
A therapeutic chemical chaperone inhibits cholera intoxication and unfolding/translocation of the cholera toxin A1 subunit M Taylor, T Banerjee, F Navarro-Garcia, J Huerta, S Massey, ... PloS one 6 (4), e18825 , 2011 2011 Citations: 35
Organophosphate-hydrolyzing enzymes as first-line of defence against nerve agent-poisoning: perspectives and the road ahead ARS Iyengar, AH Pande The protein journal 35 (6), 424-439 , 2016 2016 Citations: 32
Contribution of subdomain structure to the thermal stability of the cholera toxin A1 subunit T Banerjee, A Pande, MG Jobling, M Taylor, S Massey, RK Holmes, ... Biochemistry 49 (41), 8839-8846 , 2010 2010 Citations: 32
Involvement of a nine-residue loop of streptokinase in the generation of macromolecular substrate specificity by the activator complex through interaction with substrate … J Dhar, AH Pande, V Sundram, JS Nanda, SC Mande, G Sahni Journal of Biological Chemistry 277 (15), 13257-13267 , 2002 2002 Citations: 32
Therapeutic potential of ApoE-mimetic peptides in CNS disorders: Current perspective S Ahmed, AH Pande, SS Sharma Experimental Neurology 353, 114051 , 2022 2022 Citations: 31
Toward understanding the catalytic mechanism of human paraoxonase 1: site-specific mutagenesis at position 192 G Aggarwal, R Prajapati, RK Tripathy, P Bajaj, ARS Iyengar, ... PLoS One 11 (2), e0147999 , 2016 2016 Citations: 28
Treating liver cancer through arginine depletion YR Prasad, J Anakha, AH Pande Drug Discovery Today 29 (4), 103940 , 2024 2024 Citations: 25
Expression and purification of biologically active recombinant human paraoxonase 1 from inclusion bodies of Escherichia coli P Bajaj, RK Tripathy, G Aggarwal, AH Pande Protein expression and purification 115, 95-101 , 2015 2015 Citations: 25
Expression, purification and immobilization of recombinant AiiA enzyme onto magnetic nanoparticles C Beladiya, RK Tripathy, P Bajaj, G Aggarwal, AH Pande Protein Expression and Purification 113, 56-62 , 2015 2015 Citations: 25
